About ACOUSTICABIO, INC.
AcousticaBio is a venture-backed, NIH-funded preclinical biotechnology company spun out from Harvard in 2022. They use proprietary acoustophoretic technology to develop ultra-high-concentration subcutaneous antibody formulations for easier drug delivery.
Ultra-high concentration biologics formulation (exceeding 500 mg/mL)Microgel suspension formulations for subcutaneous deliveryProprietary acoustophoretic fluid processing technologyReduction of viscosity and aggregation in monoclonal antibodiesEnabling self-administered subcutaneous injections
Recent Federal Awards
| Award | Agency | Amount | Date |
|---|---|---|---|
| HIGH-DOSE AND SUSTAINED DELIVERY OF HIV-1 BROADLY NEUTRALIZING ANTIBODIES VIA SUBCUTANEOUS INJECTION OF HYDRO | Department of Health and Human Services | $295K |
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to ACOUSTICABIO, INC. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.